EP1337283A4 - Methods of treating vascular diseases characterized by nitric oxide insufficiency - Google Patents

Methods of treating vascular diseases characterized by nitric oxide insufficiency

Info

Publication number
EP1337283A4
EP1337283A4 EP01932915A EP01932915A EP1337283A4 EP 1337283 A4 EP1337283 A4 EP 1337283A4 EP 01932915 A EP01932915 A EP 01932915A EP 01932915 A EP01932915 A EP 01932915A EP 1337283 A4 EP1337283 A4 EP 1337283A4
Authority
EP
European Patent Office
Prior art keywords
methods
nitric oxide
vascular diseases
diseases characterized
treating vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01932915A
Other languages
German (de)
French (fr)
Other versions
EP1337283A1 (en
Inventor
Joseph Loscalzo
Joseph A Vita
Michael D Loberg
Manuel Worcel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Nitromed Inc
Original Assignee
Boston University
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/029528 external-priority patent/WO2001035961A1/en
Application filed by Boston University, Nitromed Inc filed Critical Boston University
Publication of EP1337283A1 publication Critical patent/EP1337283A1/en
Publication of EP1337283A4 publication Critical patent/EP1337283A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
EP01932915A 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency Ceased EP1337283A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US697317 1991-05-06
WOPCT/US00/29582 2000-10-26
PCT/US2000/029528 WO2001035961A1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
US09/697,317 US6635273B1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
PCT/US2001/014245 WO2002034303A1 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Publications (2)

Publication Number Publication Date
EP1337283A1 EP1337283A1 (en) 2003-08-27
EP1337283A4 true EP1337283A4 (en) 2005-05-18

Family

ID=27663595

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01932915A Ceased EP1337283A4 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Country Status (5)

Country Link
EP (1) EP1337283A4 (en)
JP (1) JP2004521083A (en)
AU (3) AU2001259399B2 (en)
CA (2) CA2678256A1 (en)
WO (1) WO2002034303A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212053A4 (en) 1999-09-08 2004-08-11 Nitromed Inc Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
FR2832634A1 (en) * 2001-11-29 2003-05-30 Univ Pasteur Use of L isomers of hydroxyguanidine aminoacid derivatives for treatment of vascular diseases with an inflammatory component
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
EP1653978B1 (en) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
ES2258365B1 (en) * 2003-10-03 2007-12-01 Lacer, S.A. DERIVATIVES OF DISULFIDE, SULFIDE, SULFOXIDE AND SULFONE OF CYCLING SUGARS AND THEIR USES.
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
ITMI20032528A1 (en) 2003-12-19 2005-06-20 Francesco Santangelo USE OF CYSTINE OR CISTEIN FOR PREVENTION AND THE
US20070191377A1 (en) * 2004-03-31 2007-08-16 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
WO2006033287A1 (en) * 2004-09-21 2006-03-30 Sankyo Company, Limited PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE
JP4949661B2 (en) * 2004-09-21 2012-06-13 第一三共株式会社 Pharmaceutical composition containing HMG-CoA reductase inhibitor and glutathione
JP2008535858A (en) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド Method for assessing genetic risk in heart failure, ie, the effect of NOS3 gene mutation
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US20070098796A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US20070232671A1 (en) * 2006-03-13 2007-10-04 Given Bruce D Methods and compositions for treatment of diastolic heart failure
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
JPWO2008069276A1 (en) 2006-12-06 2010-03-25 株式会社カネカ Cancer therapeutic agent and carcinogenesis inhibitor
ES2761224T3 (en) * 2012-02-15 2020-05-19 Kyowa Hakko Bio Co Ltd Agent to prevent or improve endothelial vascular dysfunction
EP2914257B1 (en) * 2012-10-30 2019-04-03 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
WO2014134585A1 (en) * 2013-02-28 2014-09-04 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
CN104366475B (en) * 2014-11-10 2016-01-20 罗会明 A kind of enhancement mode health products
WO2023244805A1 (en) * 2022-06-16 2023-12-21 Georgia Tech Research Corporation Anti-vwf therapeutic for preventing arterial thrombi

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327263A1 (en) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Hair growth stimulation with nitroxide and other radicals
DE4031881A1 (en) * 1990-10-08 1992-04-09 Sanol Arznei Schwarz Gmbh Solvent-free oral pharmaceutical prepn.
WO1998021193A1 (en) * 1996-11-14 1998-05-22 Nicox S.A. Antithrombotic organic nitrates
WO1999008661A1 (en) * 1997-08-15 1999-02-25 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584315A (en) * 1981-11-16 1986-04-22 The Upjohn Company Method of treating ischemic states
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
CZ4795A3 (en) * 1992-07-10 1995-07-12 Boots Co Plc Substituted cyclobut-3-ene-1,2-diones, process of their preparation and pharmaceutical composition containing thereof
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
JP4136029B2 (en) * 1997-05-12 2008-08-20 帝國製薬株式会社 Patch containing isosorbide nitrate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327263A1 (en) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Hair growth stimulation with nitroxide and other radicals
DE4031881A1 (en) * 1990-10-08 1992-04-09 Sanol Arznei Schwarz Gmbh Solvent-free oral pharmaceutical prepn.
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1998021193A1 (en) * 1996-11-14 1998-05-22 Nicox S.A. Antithrombotic organic nitrates
WO1999008661A1 (en) * 1997-08-15 1999-02-25 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Time release technology", 13 July 2011 (2011-07-13), Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Sustained_release> [retrieved on 20110713] *
A.T.TUCKER ET ALL.: "Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome a randomised trial", THE LANCET, vol. 354, 13 November 1999 (1999-11-13), pages 1670 - 1675, XP004262867 *
FARIVAR M ET AL: "FACTORIAL DESIGN-BASED OPTIMIZATION OF THE FORMULATION OF ISOSORBIDE-5-MONONITRATE MICROCAPSULES", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS, BASINGSTOKE, GB, vol. 10, no. 3, 1 July 1993 (1993-07-01), pages 309 - 317, XP000338906, ISSN: 0265-2048 *
K.H. BAUER, K.-H. FRÖMMING, C. FÜHRER: "Pharmazeutische Technologie", 1 January 1997, pages: 354 - 354 *
ONER L ET AL: "Formulation and release of dihydralazine sulphate from tabletted microcapsules.", JOURNAL OF MICROENCAPSULATION 1984 APR-JUN LNKD- PUBMED:6336521, vol. 1, no. 2, April 1984 (1984-04-01), pages 123 - 130, ISSN: 0265-2048 *
See also references of WO0234303A1 *

Also Published As

Publication number Publication date
AU2006236103B2 (en) 2009-04-02
CA2678256A1 (en) 2002-05-02
WO2002034303A1 (en) 2002-05-02
CA2421885A1 (en) 2002-05-02
EP1337283A1 (en) 2003-08-27
JP2004521083A (en) 2004-07-15
AU2001259399B2 (en) 2006-08-17
AU2006236103A1 (en) 2006-12-07
AU5939901A (en) 2002-05-06

Similar Documents

Publication Publication Date Title
EP1244455A4 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU5939901A (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
GB0014969D0 (en) Novel method of treatment
GB2393202B (en) Methods of well treatment
EP1404343A4 (en) Therapeutic combinations for the treatment of hormone deficiencies
AU2001249881A1 (en) Method of treating the heart
EP1267798A4 (en) Treatment of skin damage using polyenylphosphatidylcholine
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
EP1461027A4 (en) Treatment of neoplasia
HUP0200738A3 (en) Method of the treatment of incontinence
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
IL150479A0 (en) Treatment of psoriasis
GB0124124D0 (en) Methods of treatment
EP1389105A4 (en) Method of treatment
IL155769A0 (en) Method for the treatment of inflammation
GB2360453B (en) Treatment of skin conditions
GB0112216D0 (en) Method of treatment
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU6137801A (en) Method and composition for the treatment of angiogenesis
IL154011A0 (en) Treatment of wounds
GB0118892D0 (en) Method of treatment
GB2399500B (en) Composition and method for treatment of wounds
IL149170A0 (en) Use of nitric oxide for the treatment of airway constriction
EP1402902A4 (en) Method for treatment of vascular regeneration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030527

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050405

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/12 A

17Q First examination report despatched

Effective date: 20060502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130124